Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope

Journal of Autoimmunity

Volumn 47, Issue , 2013, Pages 83-93

  Dahan, Rony ^a,c   Gebe, John A ^b   Preisinger, Anton ^b   James, Eddie A ^b   Tendler, Mark ^a   Nepom, Gerald T ^b   Reiter, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Autoimmunity; Immunomodulation; Recombinant antibodies; T1D; TCRL; Type 1 diabetes

Indexed keywords

AUTOANTIGEN; EPITOPE; GLUTAMATE DECARBOXYLASE 65; HLA DR4 ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 2; ISOLEUCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHIONINE; RECOMBINANT ANTIBODY; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR G38H ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AUTOIMMUNITY; IMMUNOMODULATION; RECOMBINANT ANTIBODIES; T CELL RECEPTOR LIKE; T1D; TCRL; TYPE 1 DIABETES;

ANIMALS; ANTIBODIES; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; EPITOPES, T-LYMPHOCYTE; GLUTAMATE DECARBOXYLASE; HEK293 CELLS; HLA-DR4 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; IMMUNOMODULATION; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS;

EID: 84888204600     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.08.009     Document Type: Article

References (63)

1. Knip M., Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 2008, 7:550-557.
2. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965, 14:619-663.
3. Bottazzo G.F., Dean B.M., McNally J.M., MacKay E.H., Swift P.G.F., Gamble D.R. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. NEngl J Med 1985, 313:353-360.
4. Douglas Petersen L., Duinkerken G., Bruining G.J., van Lier R.A.W., de Vries R.R.P., Roep B.O. Increased numbers of invivo activated T cells in patients with recent onset insulin-dependent diabetes mellitus. JAutoimmun 1996, 9:731-737.
5. Sheehy M.J., Scharf S.J., Rowe J.R., Neme de Gimenez M.H., Meske L.M., Erlich H.A., et al. Adiabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -DQ alleles. JClin Invest 1989, 83:830-835.
6. Erlich H.A., Zeidler A., Chang J., Shaw S., Raffel L.J., Klitz W., et al. HLA class II alleles and susceptibility and resistance to insulin dependent diabetes mellitus in Mexican-American families. Nat Genet 1993, 3:358-364.
7. Lambert A.P., Gillespie K.M., Thomson G., Cordell H.J., Todd J.A., Gale E.A.M., et al. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. JClin Endocrinol Metab 2004, 89:4037-4043.
8. Verge C., Gianani R., Kawasaki E., Yu L., Pietropaolo M., Jackson R.A., et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996, 45:926-933.
9. Lampasona V., Petrone A., Tiberti C., Capizzi M., Spoletini M., di Pietro S., et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: non insulin requiring autoimmune diabetes (NIRAD) 4. Diabetes Care 2010, 33:104-108.
10. Achenbach P., Warncke K., Reiter J., Naserke H.E., Williams A.J.K., Bingley P.J., et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004, 53:384-392.
11. Nepom G.T., Lippolis J.D., White F.M., Masewicz S., Marto J.A., Herman A., et al. Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). Proc Natl Acad Sci U S A 2001, 98:1763-1768.
12. *0401) transgenicmice. Proc Natl Acad Sci U S A 1997, 94:8082-8087.
13. Reijonen H., Novak E.J., Kochik S., Heninger A., Liu A.W., Kwok W.W., et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 2002, 51:1375-1382.
14. Reijonen H., Mallone R., Heninger A.-K., Laughlin E.M., Kochik S.A., Falk B., et al. GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes 2004, 53:1987-1994.
15. Öling V., Marttila J., Ilonen J., Kwok W.W., Nepom G., Knip M., et al. GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. JAutoimmun 2005, 25:235-243.
16. Öling V., Reijonen H., Simell O., Knip M., Ilonen J. Autoantigen-specific memory CD4+ T cells are prevalent early in progression to type 1 diabetes. Cell Immunol 2012, 273:133-139.
17. Sosinowski T., Eisenbarth G. Type 1 diabetes: primary antigen/peptide/register/trimolecular complex. Immunol Res 2012, 1-7.
18. Svendsen P., Andersen C.B., Willcox N., Coyle A.J., Holmdahl R., Kamradt T., et al. Tracking of proinflammatory collagen-specific T cells in early and late collagen-induced arthritis in humanized mice. JImmunol 2004, 173:7037-7045.
19. Dahan R., Tabul M., Chou Y.K., Meza-Romero R., Andrew S., Ferro A.J., et al. TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes. Eur J Immunol 2011, 41:1465-1479.
20. Gebe J.A., Falk B.A., Rock K.A., Kochik S.A., Heninger A.K., Reijonen H., et al. Low-avidity recognition by CD4+ T cells directed to self-antigens. Eur J Immunol 2003, 33:1409-1417.
21. Bronner V., Denkberg G., Peled M., Elbaz Y., Zahavi E., Kasoto H., et al. Therapeutic antibodies: discovery and development using the ProteOn XPR36 biosensor interaction array system. Anal Biochem 2010, 406:147-156.
22. de Haard H.J., van Neer N., Reurs A., Hufton S.E., Roovers R.C., Henderikx P., et al. Alarge non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. JBiol Chem 1999, 274:18218-18230.
23. Dahan R., Reiter Y. T-cell-receptor-like antibodies - generation, function and applications. Expert Rev Mol Med 2012, 14:e6.
24. Gebe J.A., Masewicz S.A., Kochik S.A., Reijonen H., Nepom G.T. Inhibition of altered peptide ligand-mediated antagonism of human GAD65-responsive CD4+ T cells by non-antagonizable T cells. Eur J Immunol 2004, 34:3337-3345.
25. *0401. JClin Invest 1996, 98:2597-2603.
26. Ito K., Bian H.J., Molina M., Han J., Magram J., Saar E., et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. JExp Med 1996, 183:2635-2644.
27. Gebe J.A., Unrath K.A., Yue B.B., Miyake T., Falk B.A., Nepom G.T. Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice. JAutoimmun 2008, 30:197-206.
28. Gebe J.A., Falk B.E.N., Unrath K., Nepom G.T. Autoreactive T cells in a partially humanized murine model of T1D. Ann N Y Acad Sci 2007, 1103:69-76.
29. Denkberg G., Cohen C.J., Lev A., Chames P., Hoogenboom H.R., Reiter Y. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci 2002, 99:9421-9426.
30. Cohen C.J., Denkberg G., Lev A., Epel M., Reiter Y. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. JMol Recognit 2003, 16:324-332.
31. Cohen C.J., Hoffmann N., Farago M., Hoogenboom H.R., Eisenbach L., Reiter Y. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res 2002, 62:5835-5844.
32. Cohen C.J., Sarig O., Yamano Y., Tomaru U., Jacobson S., Reiter Y. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. JImmunol 2003, 170:4349-4361.
33. Denkberg G., Lev A., Eisenbach L., Benhar I., Reiter Y. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. JImmunol 2003, 171:2197-2207.
34. Lev A., Denkberg G., Cohen C.J., Tzukerman M., Skorecki K.L., Chames P., et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 2002, 62:3184-3194.
35. Makler O., Oved K., Netzer N., Wolf D., Reiter Y. Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity. Eur J Immunol 2010, 40:1552-1565.
36. Michaeli Y., Denkberg G., Sinik K., Lantzy L., Chih-Sheng C., Beauverd C., et al. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. JImmunol 2009, 182:6328-6341.
37. Epel M., Carmi I., Soueid-Baumgarten S., Oh S., Bera T., Pastan I., et al. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol 2008, 38:1706-1720.
38. Klechevsky E., Gallegos M., Denkberg G., Palucka K., Banchereau J., Cohen C., et al. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res 2008, 68:6360-6367.
39. Biddison W.E., Turner R.V., Gagnon S.J., Lev A., Cohen C.J., Reiter Y. Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes. Journal Immunol 2003, 171:3064-3074.
40. Krogsgaard M., Wucherpfennig K.W., Canella B., Hansen B.E., Svejgaard A., Pyrdol J., et al. Visualization of myelin basic protein (Mbp) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (Hla)-Dr2-Mbp-85-99 complex. JExp Med 2000, 191:1395-1412.
41. Puri J., Arnon R., Gurevich E., Teitelbaum D. Modulation of the immune response in multiple sclerosis: production of monoclonal antibodies specific to HLA/myelin basic protein. JImmunol 1997, 158:2471-2476.
42. Steenbakkers P.G.A., Baeten D., Rovers E., Veys E.M., Rijnders A.W.M., Meijerink J., et al. Localization of MHC class II/human cartilage glycoprotein-39 complexes in synovia of rheumatoid arthritis patients using complex-specific monoclonal antibodies. JImmunol 2003, 170:5719-5727.
43. Bozzacco L., Yu H., Zebroski H.A., Dengjel J., Deng H., Mojsov S., et al. Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells. JProteome Res 2011, 10:5016-5030.
44. Velazquez C., DiPaolo R., Unanue E.R. Quantitation of lysozyme peptides bound to class II MHC molecules indicates very large differences in levels of presentation. JImmunol 2001, 166:5488-5494.
45. Gebe J.A., Unrath K.A., Falk B.A., Ito K., Wen L., Daniels T.L., et al. Age-dependent loss of tolerance to an immunodominant epitope of glutamic acid decarboxylase in diabetic-prone RIP-B7/DR4 mice. Clin Immunol 2006, 121:294-304.
46. Steck A.K., Johnson K., Barriga K.J., Miao D., Yu L., Hutton J.C., et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care 2011, 34:1397-1399.
47. Mrena S., Virtanen S.M., Laippala P., Kulmala P., Hannila M.-L., Åkerblom H.K., et al. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care 2006, 29:662-667.
48. Ziegler A.-G., Nepom G.T. Prediction and pathogenesis in type 1 diabetes. Immunity 2010, 32:468-478.
49. Michels A.W., Ostrov D.A., Zhang L., Nakayama M., Fuse M., McDaniel K., et al. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. JImmunol 2011, 187:5921-5930.
50. Daniel C., Weigmann B., Bronson R., von Boehmer H. Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. JExp Med 2011, 208:1501-1510.
51. Zhang L., Stadinski B.D., Michels A., Kappler J.W., Eisenbarth G.S. Immunization with an insulin peptide-MHC complex to prevent type 1 diabetes of NOD mice. Diabetes/Metab Res Rev 2011, 27:784-789.
52. Boitard C., Bendelac A., Richard M.F., Carnaud C., Bach J.F. Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells. Proc Natl Acad Sci USA 1988, 85:9719-9723.
53. Boitard C., Michie S., Serrurier P., Butcher G.W., Larkins A.P., McDevitt H.O. Invivo prevention of thyroid and pancreatic autoimmunity in the BB rat by antibody to class II major histocompatibility complex gene products. Proc Natl Acad Sci 1985, 82:6627-6631.
54. Baudino L., Shinohara Y., Nimmerjahn F., Furukawa J.-I., Nakata M., Martínez-Soria E., et al. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. JImmunol 2008, 181:6664-6669.
55. Sievers E.L., Senter P.D. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013, 64:15-29.
56. Ezquer F., Ezquer M., Contador D., Ricca M., Simon V., Conget P. The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment. Stem Cells 2012, 30:1664-1674.
57. Lin M., Tse H., Delmastro M., Bertera S., Wong C., Lakomy R., et al. Amultivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice. Immunol Res 2011, 50:213-220.
58. Carnemolla B., Borsi L., Balza E., Castellani P., Meazza R., Berndt A., et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002, 99:1659-1665.
59. Brooks-Worrell B., Gersuk V.H., Greenbaum C., Palmer J.P. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. JImmunol 2001, 166:5265-5270.
60. Prasad S., Kohm A.P., McMahon J.S., Luo X., Miller S.D. Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. JAutoimmun 2012, 39:347-353.
61. Sergeeva A., Alatrash G., He H., Ruisaard K., Lu S., Wygant J., et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011, 117:4262-4272.
62. Wittman V.P., Woodburn D., Nguyen T., Neethling F.A., Wright S., Weidanz J.A. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. JImmunol 2006, 177:4187-4195.
63. Gebe J.A., Yue B.B., Unrath K.A., Falk B.A., Nepom G.T. Restricted autoantigen recognition associated with deletional and adaptive regulatory mechanisms. JImmunol 2009, 183:59-65.